Toronto, Ontario (FSCwire) - Chrysalis Capital IX Corporation (“Chrysalis IX” or the “Corporation”) is pleased to announce that it has entered into a definitive agreement with Inspira Financial Inc. (“Inspira”), which sets forth the general terms and conditions pursuant to which Chrysalis IX will acquire all of the issued and outstanding shares in the capital of Inspira.

About Inspira

Inspira is a private Canadian corporation focused on marketing a full range of alternative financial services to healthcare providers and their patients across the United States. Inspira currently offers revolving lines of credit to healthcare providers ranging from US$500,000 to US$5 Million via its wholly-owned subsidiary, Healthcare Receivable Lenders, Inc. (www.healthcarerl.com).

Despite the growth opportunities found in a rapidly aging population and rebounding economy, smaller healthcare providers, those with less than $50 Million in annual revenues, face a challenging finance market - traditional banks continue to reduce their risk profiles, term lenders require personal guarantees and first security over all assets, factoring lenders charge 25%+ annual interest and equipment providers have all but eliminated financing programs. By targeting this large and relatively untapped market, Inspira believes it can generate double-digit returns on government (Medicare/Medicaid) and large healthcare insurance receivables.

From a patient’s perspective, recent changes to the U.S. healthcare system, including the Affordable Care Act, has resulted in a more than quadrupling of the out of pocket deductible portion of medical procedures and services due from the patient, putting enormous pressure on the patient’s ability to pay. Inspira believes its existing relationships with healthcare providers will give it a distinct advantage to market alternative financial services directly to theses patients on a very targeted basis, dramatically reducing acquisition costs.

The Proposed Transaction

It is currently anticipated that Chrysalis IX will acquire Inspira, which will result in the Inspira shareholders holding the majority of the outstanding shares of the resulting issuer (the “Proposed Transaction”).

The Proposed Transaction is a non-arm’s length transaction as Messrs. Robert Munro and Michael Dalsin are principal shareholders, directors and officers of Chrysalis IX and principal shareholders of Inspira Financial.

Additionally, the Proposed Transaction will constitute a “related party transaction”, as that term is defined pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) and will be subject to the requirements of same. Accordingly, the Proposed Transaction is subject to the approval of the majority of the minority of Chrysalis IX’s shareholders. The Proposed Transaction has been approved by Chrysalis IX’s independent board members.

The Definitive Agreement

The definitive agreement is subject to a number of conditions precedent, including:

1. each party being satisfied with the results of its due diligence review of the other;
2. completion of an audit of the financial statements of Inspira;
3. the approval of the TSX-V;
4. the approval by the board of directors of both Inspira and Chrysalis IX of the final terms of the Proposed Transaction;
5. the resignation of certain directors and officers of Chrysalis IX, and the appointment of Inspira’s nominees; and
6. the change of the Corporation’s name

When completed, the Proposed Transaction will constitute Chrysalis IX’s qualifying transaction pursuant to the policies of the TSX Venture Exchange (“TSX-V”), and is subject to compliance with all necessary regulatory and other approvals and certain other terms and conditions.

A comprehensive press release with further particulars relating to the Proposed Transaction will follow in accordance with the policies of the TSX-V.

ABOUT CHRYSALIS CAPITAL IX CORPORATION

Chrysalis Capital IX Corporation is The Chrysalis Capital Group Inc.’s (“TCCG”) ninth capital pool company (“CPC”). TCCG is focused on generating superior shareholder returns through the creation of a series of unique CPCs. To date, TCCG has created nine Chrysalis branded CPCs and has assisted in the creation of four additional CPCs under TCCG’s partners program. For more information about TCCG, please visit www.tccg.ca.

Completion of the proposed transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information release or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSX-V has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

For more information, please contact:

Robert Munro

t: (877) 272-4073

e: contact@tccg.ca

w: www.tccg.ca

Maximum News Dissemination by FSCwire. http://www.fscwire.com

Copyright © 2014 Filing Services Canada Inc.